More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.
A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.
Concurrent CXCR4 and MYD88 L265P mutations were found to occur in patients with Waldenström macroglobulinemia.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
WM patients with high CXCR4S338X clonality had worse outcomes after ibrutinib therapy compared with patients who had low CXCR4S338X clonality.
New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
The model stratified patients into 3 risk groups based on median time to disease progression.